Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing immune-modulating drug candidates for cancer, inflammatory diseases, and other immune-mediated disorders. Its lead program, soquelitinib, is being advanced in both T cell lymphoma and atopic dermatitis, while additional candidates such as ciforadenant and mupadolimab remain in clinical development.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaLead clinical candidate targeting ITK for T cell lymphoma and immune-mediated diseases.
Clinical-stage oncology candidate designed to modulate adenosine signaling in solid tumors.
Clinical-stage immune-modulating antibody program being evaluated in cancer settings.
Additional preclinical and early clinical assets targeting immune cell function.
Asiakkaat
Corvus does not currently sell commercial products, so its near-term 'customers' are primarily clinical trial sites, contract research organizations, contract manufacturers, and academic or nonprofit research partners that support development. If approved in the future, its end customers would be physicians, hospitals, and payors treating patients with cancer or immune-mediated disease. The company’s development model is therefore driven by regulators, trial participants, and future reimbursement stakeholders rather than traditional product buyers.
CROs, CMOs, and specialist vendors that provide trial execution, manufacturing, and logistics support.
Hospitals and research centers enrolling patients and generating efficacy/safety data for the pipeline.
Research institutions that help with translational science, biomarker work, and early development.
Physicians who would prescribe approved therapies for T cell lymphoma or inflammatory disease.
Insurers and reimbursement bodies that would determine access and adoption after approval.
Strategia
Corvus is focused on advancing a small number of immune-targeted assets through clinical proof-of-concept, with soquelitinib as the lead program. The company is prioritizing indications where T-cell biology is well understood and where the same mechanism may support both oncology and inflammatory disease opportunities.
This is the lead value driver and the most advanced program in the pipeline.
Additional indications can diversify clinical risk and extend the platform beyond one asset.
The company has no commercial revenue and must manage cash carefully until approval or partnering.
Clinical-stage development is capital intensive and the company expects to need more funding.
Maantiede
Corvus is headquartered in South San Francisco, California and operates as a U.S.-based clinical-stage biotech with no owned manufacturing facilities. The company relies on third-party manufacturers and research partners, including foreign patent coverage and potential international development exposure, but it has not disclosed meaningful country-level revenue because it has not generated revenue to date.
Riskit
Corvus is exposed to the classic risks of a clinical-stage biotech: clinical failure, regulatory delay, and the need for repeated capital raises before any product revenue exists. Its dependence on third-party manufacturers and trial vendors adds execution risk, while patent protection and competition in oncology and immunology can materially affect the value of its pipeline.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
The company’s value depends on positive trial results for soquelitinib, ciforadenant, and mupadolimab.
Kohdistuu: Lead program soquelitinib and other pipeline assets
- Financing riskVaikutus: KorkeaTodennäköisyys: Korkea
Corvus has no commercial revenue and expects to continue raising capital to fund operations.
Kohdistuu: Equity dilution and funding availability
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea
FDA approval is required before commercialization and can take years with uncertain outcomes.
Kohdistuu: All product candidates
- Manufacturing and supply chain dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on third parties for drug substance, fill-finish, labeling, and distribution.
Kohdistuu: Clinical supply continuity and future commercialization
- Patent and competitive riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Competing therapies or invalidated patents could reduce the commercial opportunity.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätExpenses are recognized based on estimated vendor progress, which can shift period-to-period results.
Vaikutus: Can materially affect R&D expense and accrued liabilities
Changes in market inputs can create large non-cash gains or losses in earnings.
Vaikutus: Can distort net loss comparability across periods
A significant portion of compensation is equity-based and non-cash.
Vaikutus: Raises operating expense without immediate cash outflow
Cash runway depends on trial timing, financing access, and spending pace.
Vaikutus: Important for assessing dilution and funding risk
The South San Francisco operating lease is a principal contractual obligation through 2028.
Vaikutus: Affects right-of-use assets, lease liabilities, and fixed commitments
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Pharmaceutical Preparations
Nuvalent, Inc.
Pharmaceutical Preparations
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
Coherus Oncology, Inc.
CHRS · Biological Products, (No Diagnostic Substances)
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Immunic, Inc
IMUX · Pharmaceutical Preparations
Päivitetty: 24.9.2026